NPC Study : TAX + CIS Neoadjuvant in Patients With Loco Regionally Advanced Undifferentiated Carcinoma of Nasopharyngeal Type (UCNT)

• Status: Completed
• Trial end date: 2005-11-01

Summary

Primary Objective:

To estimate the overall response rate after neo-adjuvant chemotherapy of Docetaxel 75 mg/m2 in combination with Cisplatin 75 mg/m2 given for 3 cycles, and followed by conventional radiotherapy in UCNT.

Secondary Objectives:

To evaluate:

• The radiological response after chemotherapy and radiotherapy

• The pathological response after chemotherapy by cavum biopsy

To estimate:

• The duration of overall response

• The time to progression (T.T.P)

To analyze:

• The overall survival

• The safety profile

• Phase: Phase 2

Details

• Lead Sponsor: Sanofi
• Treatments: Docetaxel